The Technical Analyst
Krystal Biotech Inc [KRYS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Krystal Biotech Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
3.05% $162.04
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4 584.53 mill |
| EPS: | 0.390 |
| P/E: | 415.49 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 28.29 mill |
| Avg Daily Volume: | 0.400 mill |
| RATING 2024-04-23 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 415.49 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 70.68x |
| Company: PE 415.49 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$26.75 (-83.49%) $-135.29 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 154.29 - 169.80 ( +/- 4.79%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-11 | Krishnan Suma | Sell | 2 146 | Common Stock |
| 2024-03-11 | Krishnan Suma | Sell | 2 254 | Common Stock |
| 2024-03-11 | Krishnan Suma | Sell | 5 109 | Common Stock |
| 2024-03-11 | Krishnan Suma | Sell | 8 002 | Common Stock |
| 2024-03-11 | Krishnan Suma | Sell | 2 816 | Common Stock |
| INSIDER POWER |
|---|
| 4.50 |
| Last 100 transactions |
| Buy: 214 300 | Sell: 194 377 |
Forecast:
16:00 - $162.12
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $162.12
Forecast 2: 16:00 - $162.12
Forecast 3: 16:00 - $162.12
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $162.04 (3.05% ) |
| Volume | 0.219 mill |
| Avg. Vol. | 0.400 mill |
| % of Avg. Vol | 54.80 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KRYS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $110.53 | N/A | Active |
|---|
KRYS
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Last 10 Buy Signals
Latest Press Releases
2024-04-22 07:00:00 - Press Release
Krystal Biotech Announces First Patient Dosed In Phase 1 Clinical Trial Of Inhaled Kb707 For The Treatment Of Locally Advanced Or Metastatic Solid Tumors Of The Lung
• received fast track designations for both inhaled and intratumoral kb707 pittsburgh, april 22, 2024 (globe newswire) -- krystal biotech, inc. (the “company”) (nasdaq: krys), a commercial-stage biotechnology company, announced today that the first patient was dosed in its phase 1 clinical trial (kyanite-1) evaluating inhaled kb707, a modified hsv-1 vector designed to deliver genes encoding both human interleukin-12 (il-12) and interleukin-2 (il-2) to the lung, for the treatment of patients with locally advanced or metastatic solid tumors of the lung. “cytokine therapy holds significant potential for the treatment of solid tumors but its utility has been limited by a lack of safe and effective delivery options,” said david chien, m...
2024-04-04 07:00:00 - Press Release
Krystal Biotech To Present At The American Association For cancer Research 2024 Annual Meeting
Intratumoral delivery of hsv-1 encoded il-12 and il-2 enhanced local and systemic effector t-cell responses in cold tumor preclinical model intratumoral delivery of hsv-1 encoded il-12 and il-2 enhanced local and systemic effector t-cell responses in cold tumor preclinical model
2024-02-28 07:00:00 - Press Release
Krystal Biotech To Present At td Cowen 44th Annual Health Care Conference
Pittsburgh, feb. 28, 2024 (globe newswire) -- krystal biotech, inc. (the “company”) (nasdaq: krys), a commercial-stage biotechnology company, today announced that the company will participate in the td cowen 44th annual health care conference, which takes place in boston on march 4-6.
2024-02-26 08:00:00 - Press Release
Krystal Biotech Announces Fourth Quarter And Full Year 2023 Financial Results And Provides Business Updates
• net product revenue of $42.1m in 4q and $50.7m for the year • new england journal of medicine publication of the use of b-vec eyedrop formulation • reached alignment with fda to enable approval of b-vec eyedrop formulation for the treatment of lesions in the eye of deb patients • first patient dosed in phase 1 kb408 trial for the treatment of aatd; five active clinical trials in 2024 • strong balance sheet, closing the year with $594.1m in cash and investments pittsburgh, feb. 26, 2024 (globe newswire) -- krystal biotech, inc . (the “company”) (nasdaq: krys), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending december 31, 2023.
2024-02-20 07:00:00 - Press Release
Krystal Biotech To Report Fourth Quarter And Full Year 2023 Financial Results On February 26, 2024
Pittsburgh, feb. 20, 2024 (globe newswire) -- krystal biotech, inc. (the “company”) (nasdaq: krys), a commercial-stage biotechnology company, will report its fourth quarter and full year 2023 financial results on monday, february 26, 2024, prior to the open of u.s. markets. subsequently, at 8:30 am et, the company will host a webcast to discuss the financial results and provide a business update.
Latest News
2024-04-17 09:51:19 - Zacks Investment Research
Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
2024-04-04 07:00:00 - GlobeNewsWire
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
Intratumoral delivery of HSV-1 encoded IL-12 and IL-2 enhanced local and systemic effector T-cell responses in cold tumor preclinical model Intratumoral delivery of HSV-1 encoded IL-12 and IL-2 enhanced local and systemic effector T-cell responses in cold tumor preclinical model
2024-04-01 09:51:06 - Zacks Investment Research
Recent Price Trend in Krystal Biotech (KRYS) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
2024-03-27 07:44:00 - InvestorPlace
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as diseases and conditions will always need medicine and technology to treat them.
2024-03-14 17:34:14 - Seeking Alpha
Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032
Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation therapy with AAT. Newer therapies in development include elastase inhibitors, novel augmentation therapy, RNA editing, gene therapy, and RNA interference.
2024-03-14 09:51:06 - Zacks Investment Research
Krystal Biotech, Inc. (KRYS) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech, Inc. (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
2024-03-08 13:21:03 - Zacks Investment Research
Can Krystal Biotech, Inc. (KRYS) Run Higher on Rising Earnings Estimates?
Krystal Biotech, Inc. (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
2024-03-08 13:01:12 - Zacks Investment Research
Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock: Should You Buy?
Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
2024-03-08 13:01:07 - Zacks Investment Research
What Makes Krystal Biotech, Inc. (KRYS) a New Buy Stock
Krystal Biotech, Inc. (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2024-03-01 07:31:00 - The Motley Fool
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
These two mid-cap biotechs have exciting pipelines. Important breakthroughs could lead to market-beating returns.